New England Section of the American Urological Association

NEAUA Home NEAUA Home Past & Future Meetings Past & Future Meetings

Back to 2025 Abstracts

Characterizing Kidney Stone Episodes by GLP-1RA Medication in GLP-1RA Users
Sofia Maurina Di Scipio, BA1, Shreya Thiagarajan, BS2, Areeba Sadiq, MD1.
1NYU Grossman Long Island, Mineola, NY, USA, 2University of Texas at Austin Dell Medical School, Austin, TX, USA.

BACKGROUND: Glucagon-like-peptide 1 receptor agonists (GLP-1RAs) have increased in popularity as weight loss medications, but little data exists on how GLP-1RAs affect kidney stone formation. This study explores differences in kidney stone episodes between patients taking Semaglutide, Liraglutide, and Dulaglutide to determine how GLP-1RA type and duration affect stone size and recurrence.
METHODS: This retrospective study evaluated 154 patients on Semaglutide, Liraglutide, or Dulaglutide between 2011 and 2023 from an IRB approved database. All patients had new stone episodes or stone growth measured on CT between 2018 and 2023 while on GLP-1RAs. Chi square analyses were run in Microsoft Excel for surgical intervention, new stones, and stone growth. Linear regression analyses for stone burden and duration, and Kruskal-Wallis tests for stone burden and creatinine levels were run in R.
RESULTS:Semaglutide was significantly associated with a decreased risk of stone growth compared to other GLP-1RAs (p = 0.024), though GLP-1RA type was not associated with stone growth overall (p = 0.065). GLP-1RA type was not associated with a need for surgical intervention (p = 0.901), recurrence (p = 0.605), or new stones (p = 0.586). No differences were observed in Charlson Comorbidity Index (p = 0.161), median serum creatinine levels (p = 0.492) or stone burden (p = 0.550) between medications. No differences in stone composition by GLP-1RA were observed (p = 0.999). No strong linear correlation was found between duration (R = -0.148; R = -0.283; R = 0.161) and stone burden for Semaglutide, Liraglutide,or Dulaglutide, respectively.
CONCLUSIONS: Semaglutide’s significant association with lower risk of stone growth compared to other GLP-1RAs emphasizes its potential utility for high stone risk patients. These findings highlight the importance of counseling high-stone risk patients on potential GLP-1RA side effects so that patient-centered discussions guide the choice of GLP-1RAs in the management of comorbid conditions.
Back to 2025 Abstracts